Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Hall II, Ronald G ^a,b   Giuliano, Christopher A ^a,g   Haase, Krystal K ^a   Hazlewood, Kathleen A ^a,e   Frei, Chistopher R ^c   Forcade, Nicolas A ^c,h   Brouse, Sara D ^a,f   Bell, Todd ^d   Bedimo, Roger J ^b   Alvarez, Carlos A ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h Landstuhl Regional Medical Center   (United States)

Author keywords

Bacteremia; Efficacy; MRSA; Obesity; Vancomycin; Weight

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; HYPERTENSIVE AGENT; VANCOMYCIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEPHROTOXICITY; PITT BACTEREMIA SCORE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RATING SCALE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HOSPITALS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN; WEIGHTS AND MEASURES;

EID: 84862162658     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-104     Document Type: Article

References (17)

1. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994, 16:513-518. 10.1097/00007691-199410000-00013, 7846752.
2. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982, 21:575-580. 10.1128/AAC.21.4.575, 181944, 7081978.
3. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998, 54:621-625. 10.1007/s002280050524, 9860149.
4. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993, 37:436-440. 10.1128/AAC.37.3.436, 187689, 8460912.
5. Bartlett B. Pocket Book of Infectious Disease Therapy 2004, 2004. Philidelphia: Lippincott Williams & Wilkins, 12.
6. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy 2011, Sperryville, VA: Antimicrobial Therapy, Inc.
7. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98. 10.2146/ajhp080434, 19106348.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
9. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
10. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11:7-12. 10.1016/S0924-8579(98)00060-0, 10075272.
11. Zhang H, Singer B. Recursive partitioning in the health sciences 1999, New York: Springer.
12. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, Ha BC, Peck KR, Song JH. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009, 31:146-150. 10.1097/SHK.0b013e318182f98f, 18636041.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144. 10.1001/archinte.166.19.2138, 17060545.
14. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care-Associated Pneumonia: Specific Evaluation of Vancomycin Pharmacokinetic Indices. Chest 2006, 130:947-955. 10.1378/chest.130.4.947, 17035423.
15. Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control 2008, 36:118-122. 10.1016/j.ajic.2007.02.005, 18313513.
16. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320. 10.1128/AAC.00113-08, 2533486, 18591266.
17. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981. 10.1093/cid/cir124, 21460309.